Sector News

Japan tops health outcomes/spend index: UK is 23rd

November 27, 2014
Life sciences
Healthcare outcomes in the UK remain among the best in the world, but the nation spends slightly more than its peers to achieve them, according to The Economist Intelligence Unit’s Health Outcomes and Spending Index. 
 
Japan comes top of the Index – which weighs population health in 166 countries against how much they spend on health per head – scoring well on life expectancy and the overall healthiness of its population. The UK is in 23rd place, putting it at the top of six tiers for outcomes, but scoring less well than many other western European countries including France, Germany and Switzerland. UK healthcare spending is lower than in these four countries but higher than in other European countries, such as Italy and Malta, which achieve better outcomes.
 
Although incomes are affected by other factors beyond healthcare spending – including diet, lifestyles, genetics, climate and wealth levels – this does point to waste or misdirected spending within the NHS, the report comments.
 
“Cost-cutting measures and reforms have tried to address some of these problems, but the task of maintaining standards will only get more difficult and expensive as the UK population ages,” says the study’s author, Ana Nicholls. For example, UK life expectancy at age 60 is around two years lower than in Japan, and making up that gap will be extremely challenging.
 
“It is important not to view healthcare spending as a cost but as an investment, and the emphasis should be on getting good value from that investment,” says Ms Nicholls.
 
The report used World Health Organisation (WHO) figures for 2012 on disability-adjusted life years, health-adjusted life expectancy, life expectancy at age 60 and adult mortality to assess population health outcomes worldwide. It then matched these against 2012 health spending per head in nominal US dollars in the 166 countries, to explore how well their healthcare systems are working.
 
The results show that health spending generally correlates with population outcomes, but spending accelerates sharply as outcomes improve. There are also wide differences between the amounts spent by countries for similar outcomes.
 
The regional spread in terms of outcomes is marked. Asia, Europe and North America dominate the higher tiers, with the Middle East, the former Communist belt and Latin America taking up the middle. The bottom three outcome tiers are almost entirely African, with a few poorer Asian nations.
 
Japan has the best outcomes and scores comparatively well on value for money, but Singapore and South Korea achieve similar outcomes, at even lower cost. The US emerges as a poor-value healthcare system; despite spending the most per head of the 166 countries, at $9,216 in 2012, it ranks 33rd in the outcomes index, behind countries such as Lebanon and Costa Rica.
 
The poorest outcomes are in Sierra Leone and Lesotho, spending $96 and $138 per head annually, respectively. But other countries with similar HIV and infant mortality profiles, such as Mozambique and Malawi, are achieving better outcomes with far lower spending levels.
 
Other countries have low outcomes compared with their economic peers; these include South Africa, due to the HIV/AIDS epidemic, and Russia, with its short life expectancy, particularly for men. Among the wealthier countries, Denmark has disappointing outcomes, particularly for cancers.
 
By Lynne Taylor
 
Source: Pharma Times

comments closed

Related News

June 22, 2024

Ferring launches online assessment tool, educational platform around male fertility

Life sciences

Because infertility is often branded largely as a women’s issue, many men may be unaware of their own possible role in the matter and may not undergo testing in a timely manner—even though research has shown that men “substantially” contribute to about half of all cases of infertility.

June 22, 2024

Johnson & Johnson blueprints €125M plant upgrade as part of 5-year Italy investment

Life sciences

After plugging nearly 50 million euros into its Italy R&D in the first half of the decade, Johnson & Johnson Innovative Medicine is significantly upping its commitment to the country. Over the next five years, J&J Innovative Medicine, which recently rebranded from Janssen, will plug a projected 580 million euros ($621.7 million) into its Italian business, the company said in a press release.

June 22, 2024

India’s Lupin announces CEO pick for new subsidiary as it moves into the CDMO arena

Life sciences

From vitamin maker to pharmaceutical specialist and now contract manufacturer, India’s Lupin is embarking on a new phase of its corporate journey. Lupin on Monday unveiled its new subsidiary, Lupin Manufacturing Solutions, which is poised to work on the development, production and sale of active pharmaceutical ingredients.

How can we help you?

We're easy to reach